Peter Noll, a pharmaceutical company division chief, ponders the varying business models of two units that have just merged. Both have for years employed flexible, inventive strategies to good effect, but Noll is inclined to impose a single model on the combined entity. The two unit heads, however, make compelling arguments for being left to do their business as usual. What choice should Noll make? Expert commentary comes from Bodo Eickhoff, of Roche Diagnostics Deutschland, and Eric Achtmann, a tech investor and corporate adviser to Costa Coffee. For teaching purposes, this is the commentary-only version of the HBR case study. The case-only version is reprint R1503X. The complete case study and commentary is reprint R1503K.

【書誌情報】

ページ数：3ページ

サイズ：A4

商品番号：HBSP-R1503Z

発行日：2015/3/1

登録日：2015/3/27